Generic entry timeline

HISTRELIN ACETATE generics — when can they launch?

HISTRELIN ACETATE (HISTRELIN ACETATE) · · 1 active US patent · 0 expired

Earliest patent expiry
2026-06-16
expired
Full patent estate to
2026-06-16
complete protection through 2026
FDA approval
1991

Where HISTRELIN ACETATE sits in the generic timeline

All listed Orange Book patents for HISTRELIN ACETATE have expired. Generic entry is permitted, and ANDA filers can launch without patent infringement risk. Hatch-Waxman exclusivity (NCE/ODE/PED) may still apply if recently approved.

Under US Hatch-Waxman, a generic enters via an ANDA (Abbreviated New Drug Application) and may file with one of four Paragraph IV certifications attacking the brand's listed patents. If the brand sues within 45 days, a 30-month FDA approval stay is triggered. First Para IV filer typically gets 180-day market exclusivity.

Patent estate by type — active patents

Method-of-use patents only carve out specific indications; generics can launch with a "skinny label" omitting those uses. Composition-of-matter patents block the molecule itself.

  • Method of Use — 1 patent

FDA U-codes carved out by HISTRELIN ACETATE patents

Method-of-use patents are listed against specific FDA Patent Use Codes ("U-codes") representing carved-out indications. Generics can launch with a label that omits these uses.

U-codeDescription
U-1197(no description)

Sample patent estate

Showing 1 of 1 active US patents. View full estate on the HISTRELIN ACETATE drug page →

  • US8062652 Method of Use · expires 2026-06-16
    This patent protects a method of treating central precocious puberty using a controlled delivery of histrelin acetate from a polymeric material implanted in the body.
    USPTO title: Compositions and methods for treating precocious puberty

Sources

Patent term extensions (PTR, pediatric exclusivity), Hatch-Waxman 30-month stays, and FDA regulatory exclusivity (NCE/ODE/PED) may shift the effective generic entry date. Not legal advice.

Get generic entry alerts

Free Pharma CI alerts on HISTRELIN ACETATE — get notified the moment an ANDA Paragraph IV certification is filed, a 30-month stay is triggered, or a generic launches. First 2 drugs free.

Subscribe free →